{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T11:46:50Z","timestamp":1791028010527,"version":"4.1.0"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,6,4]],"date-time":"2012-06-04T00:00:00Z","timestamp":1338768000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s11910-012-0286-3","type":"journal-article","created":{"date-parts":[[2012,6,4]],"date-time":"2012-06-04T14:57:09Z","timestamp":1338821829000},"page":"399-409","source":"Crossref","is-referenced-by-count":37,"title":["Botulinum Toxin for the Treatment of Movement Disorders"],"prefix":"10.1007","volume":"12","author":[{"given":"Mary Ann","family":"Thenganatt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Fahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,6,4]]},"reference":[{"key":"286_CR1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00702-007-0728-2","volume":"115","author":"FJ Erbguth","year":"2008","unstructured":"Erbguth FJ. From poison to remedy: the chequered history of botulinum toxin. J Neural Transm. 2008;115:559\u201365.","journal-title":"J Neural Transm"},{"key":"286_CR2","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0161-6420(80)35127-0","volume":"87","author":"AB Scott","year":"1980","unstructured":"Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology. 1980;87:1044\u20139.","journal-title":"Ophthalmology"},{"key":"286_CR3","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1017\/S031716710003540X","volume":"12","author":"JK Tsui","year":"1985","unstructured":"Tsui JK, Elsen A, Mak E, et al. A pilot study on the use of botulinum toxin in spasmodic torticollis. Can J Neurol Sci. 1985;12:314\u20136.","journal-title":"Can J Neurol Sci"},{"key":"286_CR4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/archopht.1985.01050030043017","volume":"103","author":"AB Scott","year":"1985","unstructured":"Scott AB, Kennedy RA, Stubbs HA. Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol. 1985;103:347\u201350.","journal-title":"Arch Ophthalmol"},{"key":"286_CR5","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/mds.870020402","volume":"2","author":"MF Brin","year":"1987","unstructured":"Brin MF, Fahn S, Moskowitz C, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord. 1987;2:237\u201354.","journal-title":"Mov Disord"},{"key":"286_CR6","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1146\/annurev.pharmtox.44.101802.121554","volume":"44","author":"LL Simpson","year":"2004","unstructured":"Simpson LL. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol. 2004;44:167\u201393.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"286_CR7","first-page":"325","volume":"4","author":"J Frevert","year":"2010","unstructured":"Frevert J, Dressler D. Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics. 2010;4:325\u201332.","journal-title":"Biologics"},{"key":"286_CR8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1098\/rstb.1999.0377","volume":"354","author":"R Pellizzari","year":"1999","unstructured":"Pellizzari R, Rossetto O, Schiavo G, Montecucco C. Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Philos Trans R Soc Lond B Biol Sci. 1999;354:259\u201368.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"286_CR9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0022-510X(71)90129-8","volume":"14","author":"LW Duchen","year":"1971","unstructured":"Duchen LW. An electron microscopic study of the changes induced by botulinum toxin in the motor end-plates of slow and fast skeletal muscle fibres of the mouse. J Neurol Sci. 1971;14:47\u201360.","journal-title":"J Neurol Sci"},{"key":"286_CR10","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/0306-4522(81)90081-6","volume":"6","author":"RL Holland","year":"1981","unstructured":"Holland RL, Brown MC. Nerve growth in botulinum toxin poisoned muscles. Neuroscience. 1981;6:1167\u201379.","journal-title":"Neuroscience"},{"issue":"3","key":"286_CR11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0960-8966(96)00041-7","volume":"6","author":"P Juzans","year":"1996","unstructured":"Juzans P, Comella J, Molgo J, et al. Nerve terminal sprouting in botulinum type-A treated mouse levator auris longus muscle. Neuromuscul Disord. 1996;6(3):177\u201385.","journal-title":"Neuromuscul Disord"},{"key":"286_CR12","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1073\/pnas.96.6.3200","volume":"96","author":"A Paiva de","year":"1999","unstructured":"de Paiva A, Meunier F, Molgo J, et al. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A. 1999;96:3200\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"286_CR13","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/mus.880171207","volume":"17","author":"JA Hamjian","year":"1994","unstructured":"Hamjian JA, Walker FO. Serial neurophysiological studies of intramuscular botulinum-A toxin in humans. Muscle Nerve. 1994;17:1385\u201392.","journal-title":"Muscle Nerve"},{"key":"286_CR14","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/mus.880100610","volume":"10","author":"DJ Lange","year":"1987","unstructured":"Lange DJ, Brin MF, Warner CL, et al. Distant effects of local injection of botulinum toxin. Muscle Nerve. 1987;10:552\u20135.","journal-title":"Muscle Nerve"},{"key":"286_CR15","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/mus.880140711","volume":"14","author":"DJ Lange","year":"1991","unstructured":"Lange DJ, Rubin M, Greene PE, et al. Distant effects of locally injected botulinum toxin: a double-blind study of single fiber EMG changes. Muscle Nerve. 1991;14:672\u20135.","journal-title":"Muscle Nerve"},{"key":"286_CR16","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/jnnp.55.9.844","volume":"55","author":"P Girlanda","year":"1992","unstructured":"Girlanda P, Vita G, Nocolosi C, et al. Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. J Neurol Neurosurg Psychiatry. 1992;55:844\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"286_CR17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/mds.870080106","volume":"8","author":"CG Garner","year":"1993","unstructured":"Garner CG, Straube A, Witt TN, et al. Time course of distant effects of local injections of botulinum toxin. Mov Disord. 1993;8:33\u20137.","journal-title":"Mov Disord"},{"key":"286_CR18","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3109\/00016489309135834","volume":"113","author":"GM Filippi","year":"1993","unstructured":"Filippi GM, Errico P, Santarelli R, et al. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol. 1993;113:400\u20134.","journal-title":"Acta Otolaryngol"},{"key":"286_CR19","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/(SICI)1097-4598(199604)19:4<488::AID-MUS9>3.0.CO;2-8","volume":"19","author":"RL Rosales","year":"1996","unstructured":"Rosales RL, Arimura K, Takenaka S, Osame M. Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve. 1996;19:488\u201396.","journal-title":"Muscle Nerve"},{"key":"286_CR20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1468-1331.2010.03056.x","volume":"17","author":"RL Rosales","year":"2010","unstructured":"Rosales RL, Dressler D. On muscle spindles, dystonia and botulinum toxin. Eur J Neurol. 2010;17:71\u201380.","journal-title":"Eur J Neurol"},{"key":"286_CR21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.clinph.2011.05.032","volume":"123","author":"FJ Palomar","year":"2012","unstructured":"Palomar FJ, Mir P. Neurophysiological changes after intramuscular injection of botulinum toxin. Clin Neurophysiol. 2012;123:54\u201360.","journal-title":"Clin Neurophysiol"},{"key":"286_CR22","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1159\/000231337","volume":"48","author":"DA Boroff","year":"1975","unstructured":"Boroff DA, Chen GS. On the question of permeability of the blood\u2013brain barrier to botulinum toxin. Int Arch Allergy Appl Immunol. 1975;48:495\u2013504.","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"286_CR23","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1523\/JNEUROSCI.0375-08.2008","volume":"28","author":"F Antonucci","year":"2008","unstructured":"Antonucci F, Rossi C, Gianfranceschi, et al. Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci. 2008;28:3689\u201396.","journal-title":"J Neurosci"},{"key":"286_CR24","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1080\/09638280701568296","volume":"29","author":"D Dressler","year":"2007","unstructured":"Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil. 2007;29:1761\u20138.","journal-title":"Disabil Rehabil"},{"key":"286_CR25","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1002\/mds.20066","volume":"19","author":"C Sampaio","year":"2004","unstructured":"Sampaio C, Costa J, Ferreira JJ. Clinical comparability of marketed formulations of botulinum toxin. Mov Disord. 2004;19:S129\u201336.","journal-title":"Mov Disord"},{"key":"286_CR26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000067023","volume":"49","author":"D Dressler","year":"2003","unstructured":"Dressler D, Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol. 2003;49:34\u20138.","journal-title":"Eur Neurol"},{"key":"286_CR27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF03033929","volume":"9","author":"D Dressler","year":"2006","unstructured":"Dressler D, Eleopra R. Clinical use of non-A botulinum toxins: botulinum toxin type B. Neurotox Res. 2006;9:121\u20135.","journal-title":"Neurotox Res"},{"key":"286_CR28","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1212\/01.wnl.0000174433.76707.8c","volume":"65","author":"R Tintner","year":"2005","unstructured":"Tintner R, Gross R, Winzer UF, et al. Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial. Neurology. 2005;65:765\u20137.","journal-title":"Neurology"},{"key":"286_CR29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/mds.870090216","volume":"9","author":"P Greene","year":"1994","unstructured":"Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord. 1994;9:213\u20137.","journal-title":"Mov Disord"},{"key":"286_CR30","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1212\/WNL.45.9.1743","volume":"45","author":"J Jankovic","year":"1995","unstructured":"Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology. 1995;45:1743\u20136.","journal-title":"Neurology"},{"key":"286_CR31","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1212\/01.wnl.0000249308.66959.43","volume":"67","author":"J Jankovic","year":"2006","unstructured":"Jankovic J, Hunter C, Dolimbel BZ, et al. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006;67:2233\u20135.","journal-title":"Neurology"},{"key":"286_CR32","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000047963","volume":"47","author":"D Dressler","year":"2002","unstructured":"Dressler D, Munchau A, Bhatia KP, et al. Antibody-induced botulinum toxin therapy failure: can it be overcome by increased botulinum toxin doses? Eur Neurol. 2002;47:118\u201321.","journal-title":"Eur Neurol"},{"key":"286_CR33","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/mds.870080411","volume":"8","author":"PE Greene","year":"1993","unstructured":"Greene PE, Fahn S. Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A. Mov Disord. 1993;8:479\u201383.","journal-title":"Mov Disord"},{"key":"286_CR34","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00415-003-1129-6","volume":"250","author":"D Dressler","year":"2003","unstructured":"Dressler D, Bigalke H, Benecke R. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure. J Neurol. 2003;250:967\u20139.","journal-title":"J Neurol"},{"key":"286_CR35","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1212\/01.WNL.0000055087.96356.BB","volume":"60","author":"J Jankovic","year":"2003","unstructured":"Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology. 2003;60:1186\u20138.","journal-title":"Neurology"},{"key":"286_CR36","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/WNF.0b013e3181b13308","volume":"32","author":"P Kanovsky","year":"2009","unstructured":"Kanovsky P, Slawek J, Denes Z, et al. Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Clin Neuropharmacol. 2009;32:259\u201365.","journal-title":"Clin Neuropharmacol"},{"key":"286_CR37","doi-asserted-by":"crossref","first-page":"486","DOI":"10.2340\/16501977-0796","volume":"43","author":"P Kanovsky","year":"2011","unstructured":"Kanovsky P, Slawek J, Denes Z, et al. Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity. J Rehabil Med. 2011;43:486\u201392.","journal-title":"J Rehabil Med"},{"key":"286_CR38","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1002\/mds.20022","volume":"19","author":"D Dressler","year":"2004","unstructured":"Dressler D. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord. 2004;19:S92\u2013S100.","journal-title":"Mov Disord"},{"key":"286_CR39","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1006\/exnr.1997.6580","volume":"147","author":"H Goschel","year":"1997","unstructured":"Goschel H, Wohlfarth K, Frevert J, et al. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies\u2013therapeutic consequences. Exp Neurol. 1997;147:96\u2013102.","journal-title":"Exp Neurol"},{"key":"286_CR40","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/1531-8257(200009)15:5<973::AID-MDS1031>3.0.CO;2-X","volume":"15","author":"D Dressler","year":"2000","unstructured":"Dressler D, Dirnberger G, Bhatia KP, et al. Botulinum toxin antibody testing: comparison between the mouse protection assay and the mouse lethality assay. Mov Disord. 2000;15:973\u20136.","journal-title":"Mov Disord"},{"key":"286_CR41","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1212\/WNL.50.5.1463","volume":"50","author":"J Palace","year":"1998","unstructured":"Palace J, Nairne A, Hyman N, et al. A radioimmuno-precipitation assay for antibodies to botulinum A. Neurology. 1998;50:1463\u20136.","journal-title":"Neurology"},{"key":"286_CR42","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000052139","volume":"45","author":"D Dressler","year":"2001","unstructured":"Dressler D, Dirnberger G. Botulinum toxin antibody testing: comparison between the immunoprecipitation assay and the mouse diaphragm assay. Eur Neurol. 2001;45:257\u201360.","journal-title":"Eur Neurol"},{"key":"286_CR43","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1136\/jnnp.66.5.612","volume":"66","author":"PA Hanna","year":"1999","unstructured":"Hanna PA, Jankovic J, Vincent A. Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J Neurol Neurosurg Psychiatry. 1999;66:612\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"286_CR44","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/mds.870120116","volume":"12","author":"KR Kessler","year":"1997","unstructured":"Kessler KR, Benecke R. The EBD test\u2013a clinical test for the detection of antibodies to botulinum toxin type A. Mov Disord. 1997;12:95\u20139.","journal-title":"Mov Disord"},{"key":"286_CR45","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s004150070132","volume":"247","author":"D Dressler","year":"2000","unstructured":"Dressler D, Bigalke H, Rothwell JC. The sternocleidomastoid test: an in vivo assay to investigate botulinum toxin antibody formation in humans. J Neurol. 2000;247:630\u20132.","journal-title":"J Neurol"},{"key":"286_CR46","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1212\/01.wnl.0000311389.26145.95","volume":"70","author":"DM Simpson","year":"2008","unstructured":"\u2022\u2022 Simpson DM, Blitzer A, Brashera A, et al. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70:1699\u2013706. This is a systematic review of the evidence for botulinum toxin treatment in various movement disorders.","journal-title":"Neurology"},{"key":"286_CR47","first-page":"271","volume":"35","author":"S Fahn","year":"1985","unstructured":"Fahn S, List T, Moskowitz C, et al. Double-blind controlled study of botulinum toxin for blepharospasm. Neurology. 1985;35:271\u20132.","journal-title":"Neurology"},{"key":"286_CR48","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1212\/WNL.37.4.616","volume":"37","author":"J Jankovic","year":"1987","unstructured":"Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology. 1987;37:616\u201323.","journal-title":"Neurology"},{"key":"286_CR49","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.parkreldis.2007.11.003","volume":"14","author":"D Truong","year":"2008","unstructured":"Truong D, Comella C, Fernandez HH, et al. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord. 2008;14:407\u201314.","journal-title":"Parkinsonism Relat Disord"},{"key":"286_CR50","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF00941758","volume":"235","author":"Z Nussgens","year":"1997","unstructured":"Nussgens Z, Roggenkamper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol. 1997;235:197\u20139.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"286_CR51","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/mds.870120627","volume":"12","author":"C Sampaio","year":"1997","unstructured":"Sampaio C, Ferreira JJ, Simoes F, et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A\u2013Dysport and Botox\u2013assuming a ratio of 4:1. Mov Disord. 1997;12:1013\u20138.","journal-title":"Mov Disord"},{"key":"286_CR52","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00702-005-0323-3","volume":"113","author":"P Roggenkamper","year":"2006","unstructured":"Roggenkamper P, Jost WH, Bihari K, Comes G, Grafe S. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm. 2006;113:303\u201312.","journal-title":"J Neural Transm"},{"key":"286_CR53","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3341\/kjo.2009.23.3.137","volume":"23","author":"JS Yoon","year":"2009","unstructured":"Yoon JS, Kim JC, Lee SY. Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm. Korean J Ophthalmol. 2009;23:137\u201341.","journal-title":"Korean J Ophthalmol"},{"key":"286_CR54","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/WNF.0b013e3181c46f61","volume":"33","author":"EM Quagliato","year":"2010","unstructured":"Quagliato EM, Carelli EF, Viana MA. Prospective, randomized, double-blind study, comparing botulinum toxins type a botox and prosigne for blepharospasm and hemifacial spasm treatment. Clin Neuropharmacol. 2010;33:27\u201331.","journal-title":"Clin Neuropharmacol"},{"key":"286_CR55","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/mus.880150909","volume":"15","author":"DM Yoshimura","year":"1992","unstructured":"Yoshimura DM, Aminoff MJ, Tami TA, Scott AB. Treatment of hemifacial spasm with botulinum toxin. Muscle Nerve. 1992;15:1045\u20139.","journal-title":"Muscle Nerve"},{"key":"286_CR56","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3346\/jkms.1993.8.5.334","volume":"8","author":"YC Park","year":"1993","unstructured":"Park YC, Lim JK, Lee DK, Yi SD. Botulinum a toxin treatment of hemifacial spasm and blepharospasm. J Korean Med Sci. 1993;8:334\u201340.","journal-title":"J Korean Med Sci"},{"key":"286_CR57","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1212\/WNL.40.8.1213","volume":"40","author":"P Greene","year":"1990","unstructured":"Greene P, Kang U, Fahn S, et al. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology. 1990;40:1213\u20138.","journal-title":"Neurology"},{"key":"286_CR58","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1212\/WNL.53.7.1439","volume":"53","author":"A Brashear","year":"1999","unstructured":"Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999;53:1439\u201346.","journal-title":"Neurology"},{"key":"286_CR59","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/WNL.46.4.1066","volume":"46","author":"JW Brans","year":"1996","unstructured":"Brans JW, Lindeboom R, Snoek JW, et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology. 1996;46:1066\u201372.","journal-title":"Neurology"},{"key":"286_CR60","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/jnnp.64.1.13","volume":"64","author":"W Poewe","year":"1998","unstructured":"Poewe W, Deuschl G, Nebe A, et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry. 1998;64:13\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"286_CR61","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1212\/WNL.53.7.1431","volume":"53","author":"MF Brin","year":"1999","unstructured":"Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (Botulinum Toxin Type B) in Type A-Resistant cervical dystonia. Neurology. 1999;53:1431\u201338.","journal-title":"Neurology"},{"key":"286_CR62","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/mds.20403","volume":"20","author":"D Truong","year":"2005","unstructured":"Truong D, Duane DD, Jankovic J, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005;20:783\u201391.","journal-title":"Mov Disord"},{"key":"286_CR63","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.parkreldis.2010.03.002","volume":"16","author":"D Truong","year":"2010","unstructured":"Truong D, Brodsky M, Lew M, et al. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010;16:316\u201323.","journal-title":"Parkinsonism Relat Disord"},{"key":"286_CR64","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2011.05.041","volume":"308","author":"CL Comella","year":"2011","unstructured":"Comella CL, Jankovic J, Truong DD, et al. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN(R), botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011;308:103\u20139.","journal-title":"J Neurol Sci"},{"key":"286_CR65","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/jnnp.64.1.6","volume":"64","author":"T Odergren","year":"1998","unstructured":"Odergren T, Hjaltason H, Kaakkola S, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1998;64:6\u201312.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"286_CR66","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/01.wnl.0000183055.81056.5c","volume":"65","author":"CL Comella","year":"2005","unstructured":"Comella CL, Jankovic J, Shannon KM, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology. 2005;65:1423\u20139.","journal-title":"Neurology"},{"key":"286_CR67","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.21724","volume":"23","author":"EJ Pappert","year":"2008","unstructured":"Pappert EJ, Germanson T. Botulinum toxin type B vs. type A in toxin-naive patients with cervical dystonia: Randomized, double-blind, noninferiority trial. Mov Disord. 2008;23:510\u20137.","journal-title":"Mov Disord"},{"key":"286_CR68","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/mds.870040401","volume":"4","author":"MF Brin","year":"1989","unstructured":"Brin MF, Blitzer A, Fahn S, et al. Adductor laryngeal dystonia (spastic dysphonia): treatment with local injections of botulinum toxin (Botox). Mov Disord. 1989;4:287\u201396.","journal-title":"Mov Disord"},{"key":"286_CR69","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1288\/00005537-198802000-00015","volume":"98","author":"A Blitzer","year":"1988","unstructured":"Blitzer A, Brin MF, Fahn S, Lovelace RE. Localized injections of botulinum toxin for the treatment of focal laryngeal dystonia (spastic dysphonia). Laryngoscope. 1988;98:193\u20137.","journal-title":"Laryngoscope"},{"key":"286_CR70","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1288\/00005537-199106000-00010","volume":"101","author":"DD Troung","year":"1991","unstructured":"Troung DD, Rontal M, Rolnick M, et al. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope. 1991;101:630\u20134.","journal-title":"Laryngoscope"},{"key":"286_CR71","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/mds.20098","volume":"19","author":"CH Adler","year":"2004","unstructured":"Adler CH, Bansberg SF, Krein-Jones K, Hentz JG. Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia. Mov Disord. 2004;19:1075\u20139.","journal-title":"Mov Disord"},{"key":"286_CR72","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jvoice.2005.03.008","volume":"20","author":"G Woodson","year":"2006","unstructured":"Woodson G, Hochstetler H, Murry T. Botulinum toxin therapy for abductor spasmodic dysphonia. J Voice. 2006;20:137\u201343.","journal-title":"J Voice"},{"key":"286_CR73","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/00005537-199810000-00003","volume":"108","author":"A Blitzer","year":"1998","unstructured":"Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope. 1998;108:1435\u201341.","journal-title":"Laryngoscope"},{"key":"286_CR74","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/000348948909800202","volume":"98","author":"A Blitzer","year":"1989","unstructured":"Blitzer A, Brin MF, Greene PE, Fahn S. Botulinum toxin injection for the treatment of oromandibular dystonia. Ann Otol Rhinol Laryngol. 1989;98:93\u20137.","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"286_CR75","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/jnnp.53.8.633","volume":"53","author":"J Jankovic","year":"1990","unstructured":"Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry. 1990;53:633\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"286_CR76","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1212\/WNL.53.9.2102","volume":"53","author":"EK Tan","year":"1999","unstructured":"Tan EK, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology. 1999;53:2102\u20137.","journal-title":"Neurology"},{"key":"286_CR77","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.parkreldis.2010.04.007","volume":"16","author":"CD Esper","year":"2010","unstructured":"Esper CD, Freeman A, Factor SA. Lingual protrusion dystonia: frequency, etiology and botulinum toxin therapy. Parkinsonism Relat Disord. 2010;16:438\u201341.","journal-title":"Parkinsonism Relat Disord"},{"key":"286_CR78","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/jnnp.2005.083170","volume":"78","author":"JJ Kruisdijk","year":"2007","unstructured":"Kruisdijk JJ, Koelman JH, Ongerboer de Visser BW, et al. Botulinum toxin for writer's cramp: a randomised, placebo-controlled trial and 1-year follow-up. J Neurol Neurosurg Psychiatry. 2007;78:264\u201370.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"286_CR79","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1212\/WNL.42.3.627","volume":"42","author":"DM Yoshimura","year":"1992","unstructured":"Yoshimura DM, Aminoff MJ, Olney RK. Botulinum toxin therapy for limb dystonias. Neurology. 1992;42:627\u201330.","journal-title":"Neurology"},{"key":"286_CR80","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1212\/WNL.43.1_Part_1.183","volume":"43","author":"JK Tsui","year":"1993","unstructured":"Tsui JK, Bhatt M, Calne S, Calne DB. Botulinum toxin in the treatment of writer's cramp: a double-blind study. Neurology. 1993;43:183\u20135.","journal-title":"Neurology"},{"key":"286_CR81","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/mds.870100411","volume":"10","author":"R Cole","year":"1995","unstructured":"Cole R, Hallett M, Cohen LG. Double-blind trial of botulinum toxin for treatment of focal hand dystonia. Mov Disord. 1995;10:466\u201371.","journal-title":"Mov Disord"},{"key":"286_CR82","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/archneur.1996.00550070055012","volume":"53","author":"SL Pullman","year":"1996","unstructured":"Pullman SL, Greene P, Fahn S, Pedersen SF. Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients. Arch Neurol. 1996;53:617\u201324.","journal-title":"Arch Neurol"},{"key":"286_CR83","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/mds.23504","volume":"26","author":"C Lungu","year":"2011","unstructured":"Lungu C, Karp BI, Alter K, et al. Long-term follow-up of botulinum toxin therapy for focal hand dystonia: outcome at 10\u00a0years or more. Mov Disord. 2011;26:750\u20133.","journal-title":"Mov Disord"},{"key":"286_CR84","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1212\/01.WNL.0000149768.36634.92","volume":"64","author":"S Schuele","year":"2005","unstructured":"Schuele S, Jabusch HC, Lederman RJ, Altenm\u00fcller E. Botulinum toxin injections in the treatment of musician's dystonia. Neurology. 2005;64:341\u20133.","journal-title":"Neurology"},{"key":"286_CR85","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/mds.870100317","volume":"10","author":"C Pacchetti","year":"1995","unstructured":"Pacchetti C, Albani G, Martignoni E, et al. \"Off\" painful dystonia in Parkinson's disease treated with botulinum toxin. Mov Disord. 1995;10:333\u20136.","journal-title":"Mov Disord"},{"key":"286_CR86","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1017\/S0317167100038506","volume":"23","author":"C Geenen","year":"1996","unstructured":"Geenen C, Consky E, Ashby P. Localizing muscles for botulinum toxin treatment of focal hand dystonia. Can J Neurol Sci. 1996;23:194\u20137.","journal-title":"Can J Neurol Sci"},{"key":"286_CR87","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1212\/WNL.58.5.805","volume":"58","author":"FM Molloy","year":"2002","unstructured":"Molloy FM, Shill HA, Kaelin-Lang A, Karp BI. Accuracy of muscle localization without EMG: implications for treatment of limb dystonia. Neurology. 2002;58:805\u20137.","journal-title":"Neurology"},{"key":"286_CR88","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/mds.870110306","volume":"11","author":"J Jankovic","year":"1996","unstructured":"Jankovic J, Schwartz K, Clemence W, Aswad A, Mordaunt J. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord. 1996;11:250\u20136.","journal-title":"Mov Disord"},{"key":"286_CR89","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1212\/WNL.56.11.1523","volume":"56","author":"MF Brin","year":"2001","unstructured":"Brin MF, Lyons KE, Doucette J, et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology. 2001;56:1523\u20138.","journal-title":"Neurology"},{"key":"286_CR90","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1097\/00005537-200008000-00028","volume":"110","author":"P Warrick","year":"2000","unstructured":"Warrick P, Dromey C, Irish JC, et al. Botulinum toxin for essential tremor of the voice with multiple anatomical sites of tremor: a crossover design study of unilateral versus bilateral injection. Laryngoscope. 2000;110:1366\u201374.","journal-title":"Laryngoscope"},{"key":"286_CR91","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1001\/archneur.61.9.1416","volume":"61","author":"CH Adler","year":"2004","unstructured":"Adler CH, Bansberg SF, Hentz JG, et al. Botulinum toxin type A for treating voice tremor. Arch Neurol. 2004;61:1416\u201320.","journal-title":"Arch Neurol"},{"key":"286_CR92","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/mds.870120516","volume":"12","author":"J Wissel","year":"1997","unstructured":"Wissel J, Masuhr F, Schelosky L, Ebersbach G, Poewe W, et al. Quantitative assessment of botulinum toxin treatment in 43 patients with head tremor. Mov Disord. 1997;12:722\u20136.","journal-title":"Mov Disord"},{"key":"286_CR93","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1212\/WNL.45.4.822","volume":"45","author":"R Pahwa","year":"1995","unstructured":"Pahwa R, Busenbark K, Swanson-Hyland EF, et al. Botulinum toxin treatment of essential head tremor. Neurology. 1995;45:822\u20134.","journal-title":"Neurology"},{"key":"286_CR94","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1002\/mds.21019","volume":"21","author":"SA Schneider","year":"2006","unstructured":"Schneider SA, Edwards MJ, Cordivari C, et al. Botulinum toxin A may be efficacious as treatment for jaw tremor in Parkinson's disease. Mov Disord. 2006;21:1722\u20134.","journal-title":"Mov Disord"},{"key":"286_CR95","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/archneur.57.8.1190","volume":"57","author":"CH Kwak","year":"2000","unstructured":"Kwak CH, Hanna PA, Jankovic J. Botulinum toxin in the treatment of tics. Arch Neurol. 2000;57:1190\u20133.","journal-title":"Arch Neurol"},{"key":"286_CR96","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1212\/WNL.56.5.605","volume":"56","author":"C Marras","year":"2001","unstructured":"Marras C, Andrews D, Sime E, Lang AE. Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology. 2001;56:605\u201310.","journal-title":"Neurology"},{"key":"286_CR97","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s10072-003-0201-4","volume":"24","author":"M Porta","year":"2004","unstructured":"Porta M, Maggioni G, Ottaviani F, Schindler A. Treatment of phonic tics in patients with Tourette's syndrome using botulinum toxin type A. Neurol Sci. 2004;24:420\u20133.","journal-title":"Neurol Sci"},{"key":"286_CR98","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/mds.870110413","volume":"11","author":"BL Scott","year":"1996","unstructured":"Scott BL, Jankovic J, Donovan DT. Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette's syndrome. Mov Disord. 1996;11:431\u20133.","journal-title":"Mov Disord"},{"key":"286_CR99","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/mds.870130348","volume":"13","author":"MR Trimble","year":"1998","unstructured":"Trimble MR, Whurr R, Brookes G, Robertson MM. Vocal tics in Gilles de la Tourette syndrome treated with botulinum toxin injections. Mov Disord. 1998;13:617\u20139.","journal-title":"Mov Disord"},{"key":"286_CR100","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/mds.20793","volume":"21","author":"G Lagalla","year":"2006","unstructured":"Lagalla G, Millevolte M, Capecci M, et al. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord. 2006;21:704\u20137.","journal-title":"Mov Disord"},{"key":"286_CR101","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00415-009-0085-1","volume":"256","author":"G Lagalla","year":"2009","unstructured":"Lagalla G, Millevolte M, Capecci M, et al. Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling. J Neurol. 2009;256:563\u20137.","journal-title":"J Neurol"},{"key":"286_CR102","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1212\/01.WNL.0000101713.81253.4C","volume":"62","author":"WG Ondo","year":"2004","unstructured":"Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology. 2004;62:37\u201340.","journal-title":"Neurology"},{"key":"286_CR103","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/mds.23929","volume":"27","author":"R Chinnapongse","year":"2012","unstructured":"Chinnapongse R, Gullo K, Nemeth P, et al. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial. Mov Disord. 2012;27:219\u201326.","journal-title":"Mov Disord"},{"key":"286_CR104","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.23473","volume":"26","author":"A Guidubaldi","year":"2011","unstructured":"Guidubaldi A, Fasano A, Ialongo T, et al. Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease. Mov Disord. 2011;26:313\u20139.","journal-title":"Mov Disord"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-012-0286-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-012-0286-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-012-0286-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T22:54:10Z","timestamp":1713999250000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-012-0286-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,4]]},"references-count":104,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["286"],"URL":"https:\/\/doi.org\/10.1007\/s11910-012-0286-3","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,4]]}}}